Top 5 Stocks to Buy Now
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:RKTO

Rocket One Inc. Common Stock 11/12/2024 Earnings Report

Rocket One Inc. Common Stock logo
$1.08 0.00 (0.00%)
As of 06/18/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Rocket One Inc. Common Stock EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Rocket One Inc. Common Stock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rocket One Inc. Common Stock Announcement Details

Quarter
Date
11/12/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Rocket One Inc. Common Stock's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Rocket One Inc. Common Stock Earnings Headlines

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
June 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rocket-one-reports-approximately-8-4-million-in-cash-and-cash-equivalents-and-outlines-strategy-across-ai-infrastructure-spintronic-computing-for-space-and-defense-markets-302800258.html
Space Stocks Get Torched: Short Seller Calls Them 'Sci-Fi Wishes'
June 12, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/06/53178299/space-stocks-get-torched-short-seller-calls-them-sci-fi-wishes?utm_source=snapi
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel
June 19 at 1:00 AM  |  InvestPub (Ad)
Rocket One (RKTO) stock is trending after hours as retired NASA astronaut joins advisory board: Here's what you need to know
June 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rocket-one-rkto-stock-is-trending-after-hours-as-retired-nasa-astronaut-joins-advisory-board-here-s-what-you-need-to-know/ar-AA25rVpY
Zentalis Pharmaceuticals (NASDAQ:ZNTL) vs. Rocket One Inc. Common Stock (NASDAQ:RKTO) Head to Head Survey
June 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30834471
ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.
June 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rocket-one-appoints-major-general-malcolm-b-frost-ret-to-space-and-defense-advisory-board-302789753.html
See More Rocket One Inc. Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket One Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket One Inc. Common Stock and other key companies, straight to your email.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.

View Rocket One Inc. Common Stock Profile
Earnings Tools